Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Diseases: early-phase trial registry
3 of 9 indexed Retinal Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Retinal Diseases: 9 US clinical trials tracked, 3 recruiting.
Retinal Diseases is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Nanoscope Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition retinal-diseases
OPEN 3 | RECR 33% | LATE 1 | EARLY 5 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Retinal Diseases lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Diseases is recruiting below its size-band peers.
3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinal Diseases research.
Nanoscope Therapeutics accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Retinal Diseases trials plan to enrol fewer than 100 people.
Median target enrolment is 18 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Retinal Diseases research is mostly interventional.
7 interventional and 2 observational studies make up this index (77.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
The Cleveland Clinic
NCT02423213
SGLT2 Inhibitors in Geographic Atrophy
Washington University School of Medicine
NCT07174687
4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800
Duke University
NCT07024719
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations
University of Pennsylvania
NCT00481546
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT01404247
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Eye Center of Northern Colorado, P.C.
NCT01205035
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Diseases page
9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Retinal Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nanoscope Therapeutics sponsors the most Retinal Diseases trials on record, review their full trial history before evaluating a specific study. See Nanoscope Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Diseases condition card totals 9 registered trials; most-linked intervention ranibizumab 2.0mg; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.